These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17554215)

  • 1. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
    Abu-Raddad LJ; Boily MC; Self S; Longini IM
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):454-67. PubMed ID: 17554215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits.
    Elbasha EH; Gumel AB
    Bull Math Biol; 2006 Apr; 68(3):577-614. PubMed ID: 16794946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential public health impact of imperfect HIV type 1 vaccines.
    Anderson R; Hanson M
    J Infect Dis; 2005 Feb; 191 Suppl 1():S85-96. PubMed ID: 15627235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the potential public health impact of imperfect HIV vaccines.
    Blower S
    J Infect Dis; 2005 Oct; 192(8):1494-5; author reply 1495-6. PubMed ID: 16170769
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of imperfect vaccines on the evolution of HIV virulence.
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Med Hypotheses; 2006; 66(5):907-11. PubMed ID: 16442745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
    Blower S; Schwartz EJ; Mills J
    AIDS Rev; 2003; 5(2):113-25. PubMed ID: 12876900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential global market size and public health value of an HIV-1 vaccine in a complex global market.
    Marzetta CA; Lee SS; Wrobel SJ; Singh KJ; Russell N; Esparza J
    Vaccine; 2010 Jul; 28(30):4786-97. PubMed ID: 20471439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.
    Dimitrov D; Kublin JG; Ramsey S; Corey L
    EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential future impact of a partially effective HIV vaccine in a southern African setting.
    Phillips AN; Cambiano V; Nakagawa F; Ford D; Lundgren JD; Roset-Bahmanyar E; Roman F; Van Effelterre T
    PLoS One; 2014; 9(9):e107214. PubMed ID: 25207973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia.
    Gray RT; Ghaus MH; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6125-9. PubMed ID: 21703320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical study of a staged-progression HIV model with imperfect vaccine.
    Gumel AB; McCluskey CC; van den Driessche P
    Bull Math Biol; 2006 Nov; 68(8):2105-28. PubMed ID: 16868850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk compensation after HIV-1 vaccination may accelerate viral adaptation and reduce cost-effectiveness: a modeling study.
    Peebles K; Mittler JE; Goodreau SM; Murphy JT; Reid MC; Abernethy N; Gottlieb GS; Barnabas RV; Herbeck JT
    Sci Rep; 2021 Mar; 11(1):6798. PubMed ID: 33762616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
    Herbeck JT; Peebles K; Edlefsen PT; Rolland M; Murphy JT; Gottlieb GS; Abernethy N; Mullins JI; Mittler JE; Goodreau SM
    Vaccine; 2018 Jan; 36(4):514-520. PubMed ID: 29241646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus.
    Davenport MP; Ribeiro RM; Chao DL; Perelson AS
    J Virol; 2004 Oct; 78(20):11340-51. PubMed ID: 15452255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.
    Amirfar S; Hollenberg JP; Abdool Karim SS
    J Acquir Immune Defic Syndr; 2006 Oct; 43(2):219-25. PubMed ID: 16951648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.
    Schneider K; Kerr CC; Hoare A; Wilson DP
    Vaccine; 2011 Aug; 29(36):6086-91. PubMed ID: 21723902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.
    Andersson KM; Stover J
    Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 risk and vaccine acceptability in the Ugandan military.
    Hom DL; Johnson JL; Mugyenyi P; Byaruhanga R; Kityo C; Louglin A; Svilar GM; Vjecha M; Mugerwa RD; Ellner JJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):375-80. PubMed ID: 9342258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.